Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged compounds acting as apolipoprotein A (ApoA; LPA) inhibitors reported to be useful for the treatment of hyperlipidemia, coronary heart disease, ischemic stroke and myocardial infarction.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of hypertension, diabetic nephropathy, chronic kidney disease and primary aldosteronism.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described immunoproteasome inhibitors reported to be useful for the treatment of systemic lupus erythematosus and arthritis.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.